Topic: Fungal InfectionsOnychomycosis sufferers
Onychomycosis is common among persons with diabetes, who may be susceptible to bacterial infections in
onychomycotic abrasions. Among these patients, onychomycosis can also indirectly decrease peripheral
circulation, exacerbating conditions such as venous stasis and diabetic foot ulcers.
|
|
Onychomycosis treatment
Onychomycosis is very difficult and sometimes impossible to treat, and therapy is often long-term.
Therapy consists of topical treatments that are applied directly to the nails, as well as two systemic drugs,
griseofulvin and ketoconazole. Topical therapy is reserved for only the mildest onychomycosis cases. The use of
griseofulvin and ketoconazole is problematic, and there are typically high relapse rates of 50-85%.
In addition, treatment must be continued for a long duration (10-18 months for toenails), with monthly
laboratory monitoring for several side effects, including liver toxicity. Individuals taking medications
must also abstain from alcohol consumption.
In the past few years, newer oral anti onychomycosis agents have been developed, and include
itraconazole (Sporanox), terbinafine, and fluconazole (Diflucan). These agents, when taken
orally for as little as 12
weeks, bring about better cure rates and fewer side effects than either
griseofulvin or ketoconazole.
|
